Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Infigratinib - QED Therapeutics

Drug Profile

Infigratinib - QED Therapeutics

Alternative Names: BBP-831; BGJ-398; BGJ-398 phosphate; Infigratinib phosphate; NVP-BGJ398; TRUSELTIQ

Latest Information Update: 01 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Array BioPharma; BridgeBio Pharma; Novartis; Novartis Oncology; QED Therapeutics; University of Chicago
  • Class Aniline compounds; Antineoplastics; Methylurea compounds; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Cholangiocarcinoma
  • Phase III Urogenital cancer
  • Phase II Achondroplasia; Haematological malignancies; Head and neck cancer
  • Phase I Breast cancer
  • Phase 0 Glioblastoma
  • Discontinued Bladder cancer; Malignant melanoma; Solid tumours

Most Recent Events

  • 25 Feb 2021 Preregistration for Cholangiocarcinoma (Metastatic disease, Second-line therapy or greater) in Australia (PO) prior to February 2021
  • 31 Jan 2021 Preregistration for Cholangiocarcinoma (Metastatic disease, Second-line therapy or greater) in Canada (PO)
  • 03 Dec 2020 Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) approves Clinical Trial Application (CTA) to conduct the phase IIa trial of infigratinib in Gastric cancer (Metastatic disease, Late-stage disease)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top